Performance of an Automated Insulin Delivery System in People Living With Type 2 Diabetes and Insulin Resistance: First Real-World Evidence in 26,427 Users
Authors:
- Isabeau ThijsITIsabeau Thijs
- Arcelia ArrietaAAArcelia Arrieta
- Javier CastañedaJCJavier Castañeda
- Michael JoubertMJMichael Joubert
- Francesco GiorginoFrancesco Giorgino
- Jeremy Basset-SagarminagaJBJeremy Basset-Sagarminaga
- Goran PetrovskiGPGoran Petrovski
- Robert VigerskyRVRobert Vigersky
- Ohad CohenOCOhad Cohen
- 12 March 2025
- journal article
- Published by SAGE Publications in Journal of Diabetes Science and Technology
- Vol. 20 (4) , 1302-1310
Abstract
Background: Type 2 diabetes (T2D) is a phenotypically heterogeneous disease. The use of insulin is required in a significant portion of people with T2D, despite recent developments in antidiabetic medications. This study analyzes glycemic outcomes in automated insulin delivery (AID) users with T2D with different insulin requirements. Methods: This is a retrospective, real-world analysis including MiniMed 780G (MM780G) data uploaded to CareLink Personal (January 2020 to April 2024). Four cohorts were identified based on phenotypes of T2D: (A) users with total daily dose of insulin (TDD) ≥ 100 IU, (B) users with self-reported T2D, (C) users with self-reported T2D and TDD ≥ 100 IU, and (D) users with self-reported T2D and TDD <100 IU. Glycemic outcomes and insulin use were assessed post-AID, pre-AID versus post-AID, and six-month longitudinal post-AID. Results: A total of 26 427 users were included in this study, of which 18 466 in cohort A, 10 795 in cohort B, 2 834 in cohort C, and 7 961 in cohort D. Mean time in range (TIR) was 71.1% ± 12.2 for cohort A, 75.1% ±14.1 for cohort B, 72.2% ± 15.0 for cohort C, and 76.1% ± 13.6 for cohort D. Mean time below range (TBR) <70 mg/dL was ≤1% in all cohorts. The users in cohort C using the recommended optimal settings (glucose target [GT] of 100 mg/dL and active insulin time [AIT] of two hours) had a greater TIR with 78.7% ± 10.8. All cohorts increased ≥10% post-AID compared with pre-AID. Conclusions: The use of this AID is associated with effective therapy outcomes, as indicated by over 70% TIR, and appears to be safe, as demonstrated by a low TBR in a large cohort of real-life users with self-reported T2D and high or low TDD.Keywords
This publication has 28 references indexed in Scilit:
- Effects of basic carbohydrate counting versus standard dietary care for glycaemic control in type 2 diabetes (The BCC Study): a randomised, controlled trialNutrition & Diabetes, 2024
- Addressing the Burden of Multiple Daily Insulin Injections in Type 2 Diabetes with Insulin Pump Technology: A Narrative ReviewDiabetes Therapy, 2024
- Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trialThe Lancet Diabetes & Endocrinology, 2024
- The prevalence of glycemic control in patients with type 2 diabetes treated with insulin: a systematic review and meta-analysisPublic Health, 2023
- Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trialNature Medicine, 2023
- Real-World Evidence Supporting Tandem Control-IQ Hybrid Closed-Loop Success in the Medicare and Medicaid Type 1 and Type 2 Diabetes PopulationsDiabetes Technology & Therapeutics, 2022
- Heterogeneity in phenotype, disease progression and drug response in type 2 diabetesNature Medicine, 2022
- Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysisThe Lancet Diabetes & Endocrinology, 2019
- Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variablesThe Lancet Diabetes & Endocrinology, 2018
- Insulin regimens and glycemic control in different parts of Europe over 4 years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional studyDiabetes Research and Clinical Practice, 2017